Arvinas, Inc. (ARVN)
9.60
+0.26
(+2.78%)
USD |
NASDAQ |
Aug 25, 16:00
9.60
0.00 (0.00%)
After-Hours: 19:59
Arvinas EPS Diluted (Quarterly) : 2.578 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.578 |
| March 31, 2026 | -0.90 |
| December 31, 2025 | -1.038 |
| September 30, 2025 | -0.4795 |
| June 30, 2025 | -0.8384 |
| March 31, 2025 | 1.140 |
| December 31, 2024 | -0.6255 |
| September 30, 2024 | -0.6824 |
| June 30, 2024 | -0.4896 |
| March 31, 2024 | -0.9679 |
| December 31, 2023 | -2.534 |
| September 30, 2023 | -1.183 |
| June 30, 2023 | -1.247 |
| March 31, 2023 | -1.537 |
| December 31, 2022 | -1.558 |
| September 30, 2022 | -1.244 |
| June 30, 2022 | -1.316 |
| March 31, 2022 | -1.196 |
| December 31, 2021 | -1.004 |
| Date | Value |
|---|---|
| September 30, 2021 | -0.9386 |
| June 30, 2021 | -1.029 |
| March 31, 2021 | -0.8425 |
| December 31, 2020 | -0.9947 |
| September 30, 2020 | -0.7891 |
| June 30, 2020 | -0.6512 |
| March 31, 2020 | -0.5639 |
| December 31, 2019 | -0.5637 |
| September 30, 2019 | -0.5399 |
| June 30, 2019 | -0.546 |
| March 31, 2019 | -0.4598 |
| December 31, 2018 | -1.681 |
| September 30, 2018 | -3.877 |
| June 30, 2018 | -0.7055 |
| March 31, 2018 | -2.352 |
| December 31, 2017 | -0.2891 |
| September 30, 2017 | -0.1989 |
| June 30, 2017 | -0.2077 |
| March 31, 2017 | -0.1942 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -0.2295 |
| CNBX Pharmaceuticals, Inc. | -0.0001 |
| GB Sciences, Inc. | -- |
| Fulcrum Therapeutics, Inc. | -0.3433 |
| Definium Therapeutics, Inc. | -1.436 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 169.40M |
| Revenue (Quarterly) | 249.70M |
| Total Expenses (Quarterly) | 80.30M |
| Enterprise Value | 50.20M |
| Gross Profit Margin (Quarterly) | 95.92% |
| Profit Margin (Quarterly) | 67.84% |
| Earnings Yield | 1.67% |
| Normalized Earnings Yield | 2.279 |